# Junta clínica — PT-pseudo_f99f0627e536 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_f99f0627e536",
  "pid": "PT-pseudo_f99f0627e536",
  "task": 1,
  "psa": 10.0,
  "age": 70,
  "months": 2,
  "pirads": "5",
  "psad": 0.349,
  "psav": 2.0,
  "psap": 5.6,
  "vol": 28.64,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.83261764,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 10 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 29 mL. csPCa 0.83.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "112 kg",
    "height": "181 cm",
    "bmi": "34.2",
    "bp": "104/81 mmHg",
    "hr": "82 bpm",
    "smoking": "Non-smoker",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "13 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Post-prostatectomy monitoring revealed a PSA increase to 10.0 ng/mL, necessitating immediate specialist review."
    },
    {
      "s": "History",
      "t": "At age seventy, the patient works as a retired greenhouse horticulturalist and resides with his wife. After an initial PSA elevation in 2022 prompted a radical prostatectomy when he was sixty-nine, he has maintained strict surveillance protocols. His current PSA stands at 10.0 ng/mL. He reports no urinary blockage, blood in the urine, or skeletal discomfort, recording a minimal IPSS of 1 out of 35. Alcohol consumption averages twenty-six units per week, and he regularly hikes on weekends. Beyond urological matters, he completed a six-session physiotherapy regimen for persistent lower back strain and underwent baseline cognitive screening at a memory clinic; both interventions are progressing without complication. He smokes nothing and requires no daily pharmacotherapy."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth; mobility: unrestricted; asymmetry: absent. The prostatic fossa presents symmetrically without palpable irregularities. Vital signs remain stable, and systemic examination shows no acute abnormalities. While a walking frame assists him during extended ambulation, his baseline functional capacity remains solid for routine tasks."
    }
  ],
  "occupation": "retired greenhouse horticulturalist",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Memory clinic — baseline screening",
    "Physiotherapy — lower back, six sessions"
  ],
  "alcohol": "26 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 1/35 (mild LUTS)",
  "admin": "Mobility limitation (frame); ground-floor consult room preferred.",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_f99f0627e536
Task: 1

Encounter: Urology - outpatient on 13 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 70-year-old male
  - PSA: 10.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.349 ng/mL²
  - PSA velocity: 2.0 ng/mL/yr
  - Prior PSA: 5.6 ng/mL
  - Prostate volume: 28.64 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83261764 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 10 ng/mL. PI-RADS 5. PSAD 0.35. Prostate volume 29 mL. csPCa 0.83.

Vitals: weight 112 kg, height 181 cm, BMI 34.2, BP 104/81 mmHg, HR 82 bpm. Smoking: Non-smoker.

Chief complaint: Post-prostatectomy monitoring revealed a PSA increase to 10.0 ng/mL, necessitating immediate specialist review.

History: At age seventy, the patient works as a retired greenhouse horticulturalist and resides with his wife. After an initial PSA elevation in 2022 prompted a radical prostatectomy when he was sixty-nine, he has maintained strict surveillance protocols. His current PSA stands at 10.0 ng/mL. He reports no urinary blockage, blood in the urine, or skeletal discomfort, recording a minimal IPSS of 1 out of 35. Alcohol consumption averages twenty-six units per week, and he regularly hikes on weekends. Beyond urological matters, he completed a six-session physiotherapy regimen for persistent lower back strain and underwent baseline cognitive screening at a memory clinic; both interventions are progressing without complication. He smokes nothing and requires no daily pharmacotherapy.

Physical examination: DRE — texture: smooth; mobility: unrestricted; asymmetry: absent. The prostatic fossa presents symmetrically without palpable irregularities. Vital signs remain stable, and systemic examination shows no acute abnormalities. While a walking frame assists him during extended ambulation, his baseline functional capacity remains solid for routine tasks.

Patient info: retired greenhouse horticulturalist; Married; Lives with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Memory clinic — baseline screening; Physiotherapy — lower back, six sessions.
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.63
  uncertainty  +/- 0.09 epistemic (95% band 0.46-0.80); among patients I cannot tell apart the outcome was 0.95 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.66: PI-RADS 5, PSA 9.3, PSAD 0.516, age 71, DRE Normal -> DEFER (clear). He wrote: "He has a ISUP3 cancer diagnosis already and he should be recommended treatment"
  2. distance 0.72: PI-RADS 5, PSA 10.0, PSAD 0.372, age 75, DRE Normal -> BIOPSY (clear). He wrote: "Intermediate risk disease in 75yr with some comorbidity. No targeted biopsy and unclear timing (when was diagnosis and prev biopsy). Unclear if PIRADS5 was biopsied (lim…"
  3. distance 0.74: PI-RADS 5, PSA 13.5, PSAD 0.452, age 66, DRE Normal -> BIOPSY (clear). He wrote: "PIRADS 5 lesion in a man in active surveillance."

PRECEDENT: BIOPSY (weighted vote 0.64 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 49 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines state that a repeat biopsy on MRI mandates a repeat biopsy to confirm histological progression before a change in treatment strategy. It also states that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of biopsy is not decisive because the guideline makes the decision dependent on the MRI findings, which are not fully detailed here. The precedent cited by Expert 5 suggests that the decision depends on the documented grade of the prior biopsy and surveillance history, which is the variable the cohort criterion explicitly states is not resolved by the panel.

WHAT WE STILL NEED
The prior biopsy status is documented as "Positive" on the panel, which is a fact that the guideline makes decisive. The registrar must read the previous notes for the grade of the prior biopsy (Gleason or ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade and surveillance status from the previous biopsy notes, as the panel variables do not resolve the decision.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone, extraprostatic extension, and comparison against an earlier study?
  psa_trend (get_psa_trend) -> What is the serial PSA value trend (rising, flat, or falling)?
  previous_notes (get_previous_notes) -> What is the management context, including the prior biopsy grade (Gleason/ISUP), number/dates of sessions, and surveillance protocol status?
  laboratory_results (get_lab_results) -> What are the full panel results, including free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The lesion size and zone is 12 x 9 x 11 mm in the left mid-gland region. Extraprostatic extension is not evident. Comparison against an earlier study is new.

psa_trend
The serial PSA value trend is rising, with values at "Jan 2022" of "2.0", "Jul 2023" of "4.5", and "Jan 2025" of "10.0".

previous_notes
The management context includes the prior biopsy grade not being explicitly stated, the number/dates of sessions not being explicitly stated, and the surveillance protocol status not being explicitly stated.

laboratory_results
The full panel results include PSA "10.0 ng/mL" on "25 Dec 2024", Free PSA "1.28 ng/mL" on "25 Dec 2024", %Free PSA "13%" on "25 Dec 2024", Haemoglobin "14.9 g/dL" on "25 Dec 2024", WBC "5.7 x10^9/L" on "25 Dec 2024", Platelets "188 x10^9/L" on "25 Dec 2024", Creatinine "85 umol/L" on "25 Dec 2024", eGFR ">60 mL/min/1.73m2" on "25 Dec 2024", Testosterone "15.4 nmol/L" on "25 Dec 2024", Alkaline phosphatase "61 U/L" on "25 Dec 2024", LDH "185 U/L" on "25 Dec 2024".

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes provided the necessary context regarding the prior biopsy status and surveillance.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 lesion in the left mid-gland prostatic remnant.
Serial PSA value trend is rising, with values at "Jan 2022" of "2.0", "Jul 2023" of "4.5", and "Jan 2025" of "10.0".

Findings that argue AGAINST sampling this patient now:
The previous notes do not explicitly state the prior biopsy grade, number/dates of sessions, or surveillance protocol status.

WHERE THIS LEANS
The documents confirm a high-risk MRI finding and a rising PSA trend, but the critical information regarding the prior biopsy status and surveillance protocol remains unconfirmed by the retrieved notes.
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 10.00 ng/mL over 3 points spanning 36 months; velocity +2.67 ng/mL per year; doubling time about 16 months.
PROJECTION at 6 months: 16.6 ng/mL, conformal 95% band 4.8-57.9.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.59
  uncertainty  +/- 0.08 epistemic (95% band 0.42-0.75), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.63  ('supports' tier)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.59  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=0.64  (k=3 precedents)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.61 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('supports' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar—radiology_report, psa_trend, previous_notes, and laboratory_results—do not fully answer the moderator's questions regarding the prior biopsy grade or surveillance status.

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote of experts, but this decision rests on the documented prior grade, which the retrieved notes explicitly state is not recorded.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason or ISUP) of the prior biopsy? This is not answered by the retrieved documents.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? This is not answered by the retrieved documents.

WHAT CARRIES WEIGHT, AND WHY
The documented prior biopsy grade and surveillance protocol status are the most critical variables because the EAU guideline explicitly states the decision depends on this information. The rising PSA trend and PI-RADS 5 finding support further investigation, but the missing context prevents a definitive guideline-based decision.

MY SUGGESTION TO THE CHAIR
I suggest deferring the decision until the previous notes are fully reviewed to ascertain the prior biopsy grade and surveillance status, as this information is essential for applying the EAU guideline.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the high-risk MRI finding (PI-RADS 5) combined with a rising PSA trend (from 2.0 to 10.0 ng/mL) indicates a situation where the disease behavior is evolving. The decision is supported by the fusion classifier's high probability and the weighted panel vote, as the critical information regarding the prior biopsy grade was not documented in the retrieved notes. The combination of the PI-RADS 5 lesion and the PSA trajectory drove the room to conclude that further tissue sampling is necessary to guide management.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
